传统化疗栓塞联合射频消融与传统化疗栓塞治疗超声不可见早期肝细胞癌(巴塞罗那临床肝癌分期0或A期)的疗效比较
回顾2008年1月至2016年6月167例超声不可见早期肝细胞癌患者,比较单纯传统化疗栓塞(cTACE组85例)与cTACE后即刻透视引导下射频消融 targeting 瘤内碘油沉积(联合组82例)。联合组1、3、5年局部肿瘤进展率低于cTACE组(7.3%、16.5%、16.5% vs 12.5%、31.7%、37.0%,p=0.013),中位至进展时间更长(24个月 vs 18个月,p=0.037),总生存无显著差异(p=0.686)。
要点
- 超声不可见早期肝细胞癌行cTACE后即刻透视引导下射频消融 targeting 碘油沉积,局部肿瘤进展率低于单纯cTACE。
- 联合组中位至进展时间24个月,cTACE组18个月(p=0.037);两组总生存无显著差异(p=0.686)。
- 肿瘤直径>20 mm和单纯cTACE是局部肿瘤进展和至进展时间的独立危险因素。
核心结论
- cTACE后即刻透视引导下射频消融治疗超声不可见早期肝细胞癌安全有效,较单纯cTACE局部肿瘤进展更少、至进展时间更长。
研究设计与样本
- 回顾性研究,2008年1月至2016年6月纳入167例超声不可见早期肝细胞癌患者,cTACE组85例,联合组82例;联合组为cTACE后即刻透视引导下射频消融 targeting 瘤内碘油沉积;比较并发症、局部肿瘤进展、至进展时间和总生存,并行多因素分析。
诊断标准与关键数值
- cTACE组1、3、5年局部肿瘤进展率分别为12.5%、31.7%、37.0%,联合组分别为7.3%、16.5%、16.5%(p=0.013)。
临床应用与阅片要点
- 原文结论认为cTACE后即刻透视引导下射频消融是超声不可见早期肝细胞癌安全有效的治疗,较单纯cTACE局部肿瘤进展更少、至进展时间更长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the therapeutic efficacy between conventional transarterial chemoembolization (cTACE) and combined therapy using cTACE and radiofrequency ablation (RFA) in ultrasound (US)-invisible early stage hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: From January 2008 to June 2016, 167 patients with US-invisible early stage HCCs were treated with cTACE alone (cTACE group; n = 85) or cTACE followed by immediate fluoroscopy-guided RFA targeting intratumoral iodized oil retention (combined group; n = 82). Procedure-related complications, local tumor progression (LTP), time to progression (TTP), and overall survival (OS) were compared between the two groups. Multivariate analyses were performed to identify prognostic factors.
RESULTS: There was no major complication in either group. The cTACE group showed higher 1-, 3-, and 5-year LTP rates than the combined group; i.e., 12.5%, 31.7%, and 37.0%, respectively, in the cTACE group; compared to 7.3%, 16.5%, and 16.5%, respectively, in the combined group; p = 0.013. The median TTP was 18 months in the cTACE group and 24 months in the combined group (p = 0.037). Cumulative 1-, 3-, and 5-year OS rates were 100%, 93.2%, and 87.7%, respectively, in the cTACE group and 100%, 96.6%, and 87.4%, respectively, in the combined group (p = 0.686). Tumor diameter > 20 mm and cTACE monotherapy were independent risk factors for LTP and TTP.
CONCLUSION: Combined therapy using cTACE followed by fluoroscopy-guided RFA is a safe and effective treatment in US-invisible early stage HCCs. It provides less LTP and longer TTP than cTACE alone.
引用
- Lee H, Yoon CJ, Seong NJ, et al. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A). Korean J Radiol. 2018. PMID: 30386144. doi:10.3348/kjr.2018.19.6.1130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。